What is RSV?

January 19, 2023

Respiratory Syncytial Virus (RSV) is an acute virus in the lungs that may lead to severe disease.

Respiratory Syncytial Virus (RSV) is a common virus that causes an acute illness in the lungs and may lead to severe disease in people with weakened immune systems. This virus is known as the leading cause of bronchiolitis, or inflammation in the lungs, and pneumonia in children less than one year in the United States1 – it may, however, affect older adults as well. The virus is transmitted through close personal contact or mucus droplets to the lower part of the lungs causing inflammation, which may result in difficulty breathing. 



When is RSV season?

RSV season usually begins in late fall and runs through early spring. This year, RSV activity has increased in the United States after the mandated use of masks and physical distancing was suspended2. As a result, hospitalization rates of both children and older adults have increased due to RSV infection.


What are the symptoms?

Symptoms of RSV usually include1, 3: 


  • Congested or runny nose
  • Dry cough
  • Decreased appetite
  • Low-grade fever
  • Sneezing
  • Sore throat
  • Wheezing 
  • Irritability in Children


Though most people tend to have mild, cold-like symptoms, severe cases of RSV may cause:


  • Pneumonia
  • Difficulty breathing
  • Lack of oxygen
  • Worsening of respiratory conditions [Asthma, Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF)] 


People who are infected with RSV become contagious one or two days before demonstrating symptoms and are usually contagious for three to eight days. 


How do I prevent RSV infection?

Similar to the flu virus, RSV is transmitted through close contact with sick people and contaminated surfaces. Steps taken to prevent the spread of RSV include1: 


  • Wearing a mask
  • Covering your mouth and nose when coughing or sneezing with a tissue or upper shirt sleeve
  • Washing your hands often with soap and water, or hand sanitizer when soap and water is not available
  • Avoiding close contact with sick individuals
  • Cleaning frequently touched surfaces such as doorknobs, tables, and mobile devices constantly


What are the treatment options for Infants?


Treatment of RSV is based on the direct management of symptoms which includes hydration, respiratory support, and frequent monitoring of the disease’s status. 


The only approved therapy for the prevention of RSV is Palivizumab whose brand name is Synagis®. However, this treatment is only available for premature infants.


Other therapies include inhaled bronchodilators, inhaled hypertonic saline, and corticosteroids. Corticosteroids are not routinely recommended for symptom treatment unless the RSV infection has triggered a worsening of the existing lung disorder in older children and adults4. 


What are the treatment options for Adults?

For adults with a higher risk of RSV infection, including those with chronic heart and lung disease, those with weakened immune systems, and the elderly (65 years of age and older), there is no approved therapy for prevention or treatment of RSV. Patients who have been hospitalized due to RSV infection are treated with oxygen and fluids for hydration to manage their symptoms. Other therapies that may be used include bronchodilators and corticosteroids.


Although there are few treatment options for RSV infection, studies to develop vaccines and medications are ongoing. The approval of these drugs will help lower RSV infection and healthcare costs in the community. 






A stethoscope is laying on a piece of paper next to a pen
December 12, 2024
URAC accreditation reflects ProCare Rx’s commitment to achieving and maintaining the highest quality, member engagement and experience, and operational standards for PBMs in the industry
By Mc-Rx Team November 15, 2024
Mental health parity and medication adherence
By MC-Rx Clinical Team August 7, 2024
Understanding GLP-1 Medications The landscape of obesity management is evolving, with GLP-1 receptor agonist (RA) medications emerging as a significant player. These FDA-approved drugs have proven effective in helping individuals lose weight, prompting a shift in how they are viewed and covered by health plans. However, the cost implications and strategic decisions surrounding these medications require careful consideration by employer groups and their members. The Case for GLP-1 Medications GLP-1 RAs, originally developed for diabetes management, have shown remarkable efficacy in weight loss. With the growing prevalence of obesity and its associated healthcare costs, there's increasing pressure on health plans to cover these medications. Despite their high cost—annual retail pharmacy expenses can exceed $10,000 per patient—GLP-1 RAs offer potential downstream savings by reducing obesity-related comorbidities such as diabetes, hypertension, and cardiovascular disease​​. Balancing Coverage and Cost Historically, weight loss medications were deemed "lifestyle" drugs and excluded from coverage. However, the rising popularity of GLP-1 RAs and their demonstrated benefits are challenging this perspective. For plan sponsors, the decision to cover these medications involves balancing the high upfront costs with the potential for long-term savings on medical expenses related to obesity. Cost-Containment Strategies For payers choosing to cover GLP-1 medications, several cost-containment strategies can be employed: Formulary Management : Deciding on the placement of these medications within the formulary is crucial. Options range from not covering the drugs to placing them on a high-cost tier with patient cost-sharing. Prior Authorization and Step Therapy : Implementing these measures ensures that only patients with a proper diagnosis (e.g., ICD-10 code for obesity) access these medications, preventing misuse and overutilization. Prerequisite Programs : Requiring participation in wellness or nutrition programs before approving weight loss medications can encourage lifestyle modifications that complement pharmacological treatment. Specialist Restrictions : Limiting prescriptions to weight loss specialists, such as bariatric doctors or endocrinologists, ensures appropriate therapy and monitoring. Duration Limits : Establishing treatment guidelines, such as discontinuing medications if a target weight loss is not achieved within six months, helps manage long-term costs​​. The Role of Brokers and Employer Groups Brokers play a pivotal role in guiding employer groups through the complexities of covering GLP-1 medications. Understanding the cost-benefit dynamics and available cost-containment strategies enables brokers to provide informed recommendations that align with their clients' financial and health objectives. Employer groups, in turn, must weigh the potential benefits of covering these medications against their budgetary constraints and the overall well-being of their workforce. Member Education and Engagement Effective communication with members is essential to ensure they understand the coverage options and adhere to prescribed treatments. Educational initiatives can include: Patient Communication Programs : Providing information on medication adherence, compliance, and lifestyle modifications. Continuing Education : Ongoing programs to keep members informed about the benefits and proper use of weight loss medications. Monitoring and Support : Utilizing pharmacy and medical data to track outcomes and adjust strategies as needed​​. Balance the Scale with Expert Guidance from MC-Rx The adoption of GLP-1 medications for weight loss represents a significant advancement in obesity management. However, the high costs associated with these drugs necessitate careful planning and strategic implementation by brokers, employer groups, and members. By employing robust cost-containment strategies and prioritizing member education, health plans can navigate the financial challenges while delivering meaningful health benefits to their populations. MC-Rx, as a full-service pharmacy benefits manager, offers the expertise and tools to help clients optimize their coverage decisions and manage the complexities of incorporating GLP-1 medications into their health plans. Here are just a few of the GLP-1 strategies we use to shield our clients from excessive costs: Implementation of Drug Management Tools, which is critical to ensure proper utilization for GLP-1s. Strategic Benefit Design, which also protects clients from improper GLP-1 utilization. Clear Member Communication, which is crucial for proper adherence and compliance. When implemented with an existing client, the above-listed strategies helped them achieve $382,000 in cost avoidance for GLP-1s. With the right approach, the benefits of these medications can be realized, contributing to better health outcomes and potentially lowering overall healthcare costs in the long run. For more information on managing GLP-1 medications and other pharmacy benefits, reach out to an MC-Rx expert today .
By MC-Rx Clinical Team August 2, 2024
Mental Health Parity and Medication Adherence
March 21, 2024
MC-Rx, powered by ProCare Rx, has been notified by the Academy of Managed Care Pharmacy (AMCP) of the acceptance of their abstract, “Improving Adherence to HIV PREP via a PBM-Driven Educational Intervention” , for presentation at AMCP 2024 Conference in April.
February 23, 2024
Exploring the rising costs and demands of weight-loss medication and how to combat those costs, significantly lowering drug costs for payors and increasing access for patients who need them.
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 16, 2024
A message from Marileny Lugo, President, MC-Rx
January 10, 2024
To decrease the burden on healthcare costs, at MC-Rx we strive to create awareness by educating our community regarding the importance of prevention.
September 28, 2023
Increased medication adherence has been linked to better clinical and financial outcomes.
More Posts
Share by: